Kok M, Koornstra R, Mook S, Hauptmann M, Fles R, Simon I, Glas A, Jansen M, Berns E, Linn S, Van ‘t Veer L. Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer. The Breast. 2012 Dec 21(6); 769-78 Zwart W, Theodorou V, Kok M, Canisius S, Linn S, Carroll JS. Oestrogen receptor-co-factorchromatin specificity in the transcriptional regulation of breast cancer. EMBO J. 2011 Oct 14;30(23):4764-76. Kok M, Van Schaik R, Sweep F, Van Vliet M, Look M, Van Fessum M, Meijer-Van Gelder M, Seynaeve C, Lindemans J, Wesseling J, Van ‘t Veer L, Span P, Van der Graaf W, Sleijfer S, Foekens J, Linn S, Berns E. Cytochrome P450 2C19*2 genotype predicts favorable outcome after tamoxifen treatment of advanced breast cancer. Pharmacogenomics. 2011 Aug;12(8):1137-46 Kok M, Zwart W, Holm C, Fles R, Hauptmann M, Van ‘t Veer L, Wessels L, Neefjes J, Stal O, Linn S, Landberg G, Michalides R. PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res Treat. 2011 Jan;125(1):1-12 Kok M, Linn SC. Gene expression profiles of the oestrogen receptor in breast cancer. Neth J Med. 2010 Oct;68(10):291-302 Kok M, Holm C, Hauptmann M, Stal O, Linn S, Landberg G. Phosphorylation of the oestrogen receptor at serine 118 predicts tamoxifen response: results from a randomized controlled trial. J Natl Cancer Inst. 2009 Dec 16;101(24):1725-9 Roepman P, Horlings H, Krijgsman O, Kok M, Bueno de Mesquita J, Bender R, Linn S, Glas A, Van de Vijver M. Microarray based determination of ER, PR and HER2 receptor status in breast cancer. Clin Cancer Res. 2009 Nov 15;15(22):7003-11 Kok M, Koornstra R, Margarido T, Fles R, Armstrong N, Linn S, Van ‘t Veer L, Weigelt B. Mammosphere-derived gene set predicts outcome in ER-positive breast cancer. J Pathol. 2009;218(3):316-26. Kok M, Linn S, van de Vijver M. Estrogen receptor phenotypes defined bij gene expression profiling. Cancer Treat Res. 2009;147:1-18. Kok M, Holm C, Michalides R, Fles R, Koornstra R, Wesseling J, Hauptmann M, Neefjes J, Peterse J, Stål O, Landberg G, Linn S. Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer. J Pathol. 2009;217(3):372-9. Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, Glas AM, Peterse JL, Hauptmann M, Foekens JA, Klijn JG, Wessels LF, Van't Veer LJ, Berns EM. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2009;113(2):275-83 Reyal F, Van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, Kok M, Teschendorff AE, Mook S, Van't Veer L, Caldas C, Salmon RJ, Van de Vijver MJ, Wessels LF. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of Proliferation, Immune response and RNA splicing modules in breast cancer. Breast Cancer Research 2008;10(6):R93 White PS, Thompson PM, Gotoh T, Okawa ER, Igarashi J, Kok M, Winter C, Gregory CG, Hogarty MD, Maris JM, Brodeur GM. Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene 2005 ; 24(16) : 2684-94 Thompson PM, Gotoh T, Kok M, White PS, Brodeur GM. CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene 2003;22(7):1002-11 Kok M, Bonfrer JM, Korse CM, de Jong D, Kersten MJ. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin’s lymphoma. Tumorbiology 2003; 24:53-60